PubMed: 33965067 Phase 2a: Weight Loss Efficacy Study (NCT03224429) Study Title: "Efficacy and Safety of Cagrilintide for Weight Management in Adults With Overweight or Obesity" Status: Completed Phase: Phase 2a Enrollment: 706 participants Study Period: 2018-2020 Location: Multi-country (US, Europe) Design: Randomized, double-blind, placebo-controlled Duration: 26 weeks Intervention: Cagrilintide 0.6/1.2/2.4/4.5 mg weekly Population: BMI 30 or 27 with comorbidity, no diabetes Key Results (26 Weeks): Mean Weight Loss: 10.8% at 4.5 mg (highest dose) 8.6% at 2.4 mg 6.0% at 1.2 mg 4.3% at 0.6 mg 3.0% with placebo 10% Weight Loss: 51% (4.5 mg) vs
5:F1000 Faculty Rev-951 Published 2016 May 20
Even if Intrinsic Factor is lacking, the sheer concentration of the liquid forces approximately 1-2% of the dose directly into the bloodstream, ensuring adequate delivery to the tissues
Nalecz, Nencki Institute of Experimental Biology (PAS), Poland
His last name means "little mouse" in Italian
Both medications share common GLP-1 side effects like nausea, vomiting, and constipation, particularly during initial weeks
